Research has also shown that the binding of daratumumab to CD38 modifies cytoskeleton reorganization in MM cells by inducing a redistribution of CD38 antigens into polar aggregates that are released into the BM microenvironment. The gene discussed is CD38; the disease is Miyoshi myopathy.